Clinical Data New data build case for Roche’s oral BTK drug for MS PharmaphorumRoche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.Clinical DataNeuroscienceRead full story pharminent April 22, 2026 (Last updated: April 22, 2026) Pharmaphorum Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns. Clinical DataNeuroscienceRead full story Post navigation Previous: Pivotal trial of Moderna’s H5N1 bird flu jab gets underwayNext: MSD-backed Ray locks in $125m to back eye drug pipeline Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026